Drug General Information (ID: DDIU36QMBJ)
Drug Name			Bicalutamide		Drug Info		Lefamulin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Antibiotics
Structure

Mechanism of Bicalutamide-Lefamulin Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Bicalutamide				Lefamulin
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Bicalutamide and Lefamulin

Recommended Action
Management		Coadministration of lefamulin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have electrocardiograms (ECGs) and electrolyte levels assessed during treatment as appropriate based on individual risk factors. The recommended dosage and infusion rate of lefamulin should not be exceeded, as the magnitude of QT prolongation may increase with increasing concentrations of the drug or increasing the rate of infusion.

References
1	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.